Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Cash flows from operating activities:
Net income (loss)	$ (22,414,640)	$ (5,229,725)	$ (26,671,857)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	479,595	512,366	389,439
Amortization		13,147	17,850
Unrealized currency loss on short-term investments	52,726
Loss on equipment disposal	18,997
Noncash compensation	2,535,217	4,044,858	6,662,130
Warrant issuance costs	244,857	150,827	231,980
Change in value of warrant liability	(7,701,981)	(19,821,787)	16,011,769
Patent costs		1,481,318
Changes in operating assets and liabilities:
Accounts receivable	1,736,199	3,641,491	(1,990,774)
Other current assets	(182,428)	123,197	(611,885)
Other long-term assets	(6,414)	(919)	(8,656)
Accounts payable	609,522	(348,282)	53,370
Deferred revenue	3,238,124	(2,317,218)	(12,398)
Accrued expenses	740,723	845,337	29,701
Net cash used in operating activities	(20,649,503)	(16,905,390)	(5,899,331)
Cash flows from investing activities:
Purchase of short-term investments	(5,220,781)	(5,520,000)	(459,364)
Sale of short-term investments	8,312,120	434,835
Purchase of equipment	(178,271)	(655,553)	(465,650)
Increase in restricted cash	(1,541,366)
Investment in patents		(326,171)	(250,735)
Net cash provided by (used in) investing activities	1,371,702	(6,066,889)	(1,175,749)
Cash flows from financing activities:
Issuance of common stock, net of offering costs	15,675,727	21,946,801	12,234,693
Exercise of options	2,375	532,408	901,911
Repayment of capital lease obligation	(52,410)
Exercise of warrants		949,793	418,926
Net cash provided by financing activities	21,519,249	34,769,442	17,065,094
Effect of exchange rate change on cash and equivalents	538,046	156,889	(34,577)
Increase in cash and cash equivalents	2,779,494	11,954,052	9,955,437
Cash and cash equivalents at beginning of period	22,872,589	10,918,537	963,100
Cash and cash equivalents at end of period	25,652,083	22,872,589	10,918,537
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	23,708
Supplemental schedule of noncash financing activities:
Equipment acquired through lease financing	221,690
Conversion of warrant liability to equity upon warrant exercise		995,428	2,020,031
Noncash financing costs on common stock offering		207,905	227,486
Noncash warrant issuance costs		19,361	91,283
Incuron [Member]
Cash flows from financing activities:
Noncontrolling interest capital contribution	5,893,557	2,340,374	3,509,564
Panacela [Member]
Cash flows from financing activities:
Noncontrolling interest capital contribution		$ 9,000,066